Bullous Pemphigoid Patients Face Higher Risk of Osteoporosis and Hip Fractures: Study Suggests

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-08-28 15:00 GMT | Update On 2025-08-28 15:00 GMT

Israel: A new population-based study published in Archives of Dermatological Research reveals that individuals with bullous pemphigoid (BP) face a significantly increased risk of bone-related complications, including osteoporosis and femoral head fractures (FHF). The research, led by Dr. Khalaf Kridin from the Unit of Dermatology and Skin Research Laboratory, Galilee Medical Center, Israel, highlights the need for vigilant bone health management in this vulnerable group.

BP, an autoimmune blistering disorder primarily affecting older adults, has been associated with systemic complications in recent years. However, its potential link to skeletal health has remained poorly understood. This study aimed to quantify the risk of osteoporosis and FHF among BP patients and assess the influence of treatment regimens on these outcomes.

The retrospective cohort analysis utilized data from Clalit Health Services, Israel’s largest healthcare database, including 3,924 newly diagnosed BP patients and 19,280 matched controls. Researchers estimated incidence rates and hazard ratios (HRs) for osteoporosis and FHF using multivariate Cox regression, adjusting for demographic and clinical factors. The impact of different therapeutic strategies—systemic corticosteroids (SCS), topical corticosteroids (TCS), and adjuvant immunosuppressants—was also evaluated.

The key findings of the study were as follows:

BP patients had a 66% higher risk of osteoporosis compared to controls (adjusted HR 1.66).
BP patients faced a 23% increased risk of femoral head fractures (adjusted HR 1.23).
Systemic corticosteroids significantly raised osteoporosis risk compared to topical therapy (HR 1.59).
A combination of systemic corticosteroids with immunosuppressants further amplified osteoporosis risk, while systemic corticosteroid monotherapy showed a lower risk (HR 0.38).
Treatment type did not significantly impact femoral head fracture incidence.
Femoral head fractures were associated with a 42% higher mortality risk (HR 1.42).

“These findings indicate that BP is an independent risk factor for osteoporosis and femoral head fractures,” the authors noted. The strong association with systemic corticosteroid use suggests a need for cautious prescribing and proactive preventive measures, such as bone density monitoring and fracture risk assessment. Strategies like calcium and vitamin D supplementation, bisphosphonate therapy, and lifestyle interventions could play a crucial role in reducing the burden of skeletal complications in BP patients.

Given the aging population and the growing prevalence of BP, this study highlights the importance of integrating bone health surveillance into the routine care of patients, especially those undergoing systemic corticosteroid therapy.

"These results emphasize the importance of active bone health monitoring and implementing fracture prevention strategies in BP patients, especially those receiving systemic corticosteroid therapy," the authors concluded.

Reference:

Kaplan, B., Abu-Khalil, M., Kaykov, E. et al. Bone-related outcomes in patients with bullous pemphigoid: a population-based study. Arch Dermatol Res 317, 846 (2025). https://doi.org/10.1007/s00403-025-04347-z

Article Source : Archives of Dermatological Research

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Bullous Pemphigoid Patients Face Higher Risk of Osteoporosis and Hip Fractures: Study Suggests

Similar News

Increased TB Risk in Psoriasis Patients on Etanercept Despite Isoniazid Prophylaxis: Study

Dupilumab Shows High Efficacy and Safety in Treating Moderate to Severe Prurigo Nodularis: Study

Topical Dimethylglycine Sodium Salt and Caffeine Shampoo Promising for Treating Male Pattern Baldness: Study

Vitamin B5 Injections Don't Outperform Topical Therapy for Acne, Clinical Trial Reports

US FDA issued warning against manufacturers of mousse or whipped cream sunscreen products

Scientists Grow World's First Fully Functional Human Skin with Blood Supply

Low-Dose Oral Minoxidil for Hair Loss Not Linked to Tachycardia, Large Study Suggests